Millions of high-strength opioid tablets manufactured in India are reportedly continuing to flood West Africa, despite pledges of regulatory crackdowns. This influx is fueling an escalating addiction crisis and contributing to the spread of "kush," a deadly street narcotic often referred to as a "zombie drug."
Tapentadol: The Opioid at the Center of the Crisis
The synthetic opioid at the heart of the controversy is tapentadol, a powerful painkiller. It is sold openly in blister packs, resembling ordinary medicine, at roadside kiosks and informal pharmacies across countries like Sierra Leone, Nigeria, and Ghana. Alarmingly, many of the exported tablets are of strengths—specifically 225mg and 250mg—that are not approved by regulators anywhere in the world for therapeutic use.
Experts, including Professor Andrew Somogyi of the University of Adelaide, question the approval of such high doses, suggesting they might be designed to bypass regulatory and commercial restrictions.
From Painkiller to "Zombie Drug"
The crisis has intensified as tapentadol is now reportedly being mixed into kush, a highly addictive synthetic street drug. This potent combination is blamed for widespread social collapse in parts of West Africa, turning users into near-catatonic figures, hence the grim moniker "zombie drug."
Both Sierra Leone and Liberia have declared national emergencies over the crisis. Ansu Konneh, Director of Mental Health at Sierra Leone’s Ministry of Social Welfare, described the emergence of tapentadol-laced kush as "very alarming," citing daily collections of bodies from streets and slums, with over 400 corpses reportedly recovered in Freetown within three months.
Public health researcher Ronald Abu Bangura noted that traffickers grind the opioid tablets and incorporate them into kush, drastically increasing its potency and addictive effects.
Tracking Indian Pharmaceutical Firms
An investigation traced several seized opioid consignments back to Indian manufacturers by matching licence numbers on confiscated packs with export databases. Firms named in the investigation include Gujarat Pharmaceuticals, Merit Organics, McW Healthcare, PRG Pharma, and Syncom Formulations.
- Tablets seized in Sierra Leone and Guinea carried licence numbers linked to Gujarat-based manufacturers.
- Senegalese authorities intercepted 250mg tapentadol tablets connected to McW Healthcare.
- Syncom Formulations was identified as a major exporter of tapentadol to West Africa, with shipments allegedly worth nearly $15 million after a recent crackdown.
Some consignments were reportedly labeled "Harmless Medicines for Human Consumption." Notably, PRG Pharma was also linked through shareholding connections to Maiden Pharmaceuticals, an Indian firm previously implicated in child deaths in Gambia due to contaminated cough syrup.
Nigerian authorities have described some imports as "illegal" due to the absence of required pharmaceutical permits for the importers.
Regulatory Questions and India's Response
Although India officially classified tapentadol as a controlled narcotic in 2018, it reportedly faces fewer international controls compared to tramadol, another opioid widely abused in West Africa. This regulatory disparity has made tapentadol easier to export.
India announced a "zero-tolerance" approach to illegal opioid exports earlier this year and subsequently banned exports of tapentadol combinations containing carisoprodol, pledging tighter controls. However, reports indicate that large-scale exports of pure tapentadol tablets persist.
The Central Drugs Standard Control Organisation (CDSCO) stated it had "no record" of issuing export clearances for several consignments involving the high-strength 225mg and 250mg tablets, but did not respond to further inquiries. The Indian Drug Manufacturers’ Association maintains that manufacturers complying with export procedures cannot be held responsible for the diversion or misuse of products further down the supply chain.